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Abstract
The pathogenicity of previously published disease-associated genes and variants is sometimes questionable. Large-scale,
population-based sequencing studies have uncovered numerous false assignments of pathogenicity. Misinterpretation of
sequence variants may have serious implications for the patients and families involved, as genetic test results are increasingly
being used in medical decision making. In this study, we assessed the role of the calreticulin-3 gene (CALR3) in
cardiomyopathy. CALR3 has been included in several cardiomyopathy gene panels worldwide. Its inclusion is based on a
single publication describing two missense variants in patients with hypertrophic cardiomyopathy. In our national
cardiomyopathy cohort (n= 6154), we identiﬁed 17 unique, rare heterozygous CALR3 variants in 48 probands. Overall, our
patient cohort contained a signiﬁcantly higher number of rare CALR3 variants compared to the ExAC population (p=
0.0036). However, after removing a potential Dutch founder variant, no statistically signiﬁcant difference was found (p=
0.89). In nine probands, the CALR3 variant was accompanied by a disease-causing variant in another, well-known
cardiomyopathy gene. In three families, the CALR3 variant did not segregate with the disease. Furthermore, we could not
demonstrate calreticulin-3 protein expression in myocardial tissues at various ages. On the basis of these ﬁndings, it seems
highly questionable that variants in CALR3 are a monogenic cause of cardiomyopathy.
Introduction
Cardiomyopathies are a heterogeneous group of disorders
affecting the myocardium. Variants in genes encoding
sarcomeric and Z-disc proteins, including cardiac myosin-
binding protein C (MYBPC3), β-myosin heavy chain
(MYH7), and titin (TTN), account for the majority of cases
[1]. Chiu et al. [2] hypothesized that variants in genes
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encoding calcium-regulating proteins may be involved in
the remainder. In their study, a cohort of 252 unrelated
patients with hypertrophic cardiomyopathy was screened
for variants in several candidate genes involved in cal-
cium regulation, including the CALR3 gene (MIM
611414). Two heterozygous missense variants c.218G>A
p.(Arg73Gln) and c.245A>G p.(Lys82Arg) in CALR3
were considered of “pathogenic signiﬁcance”. Both var-
iants were reported to affect conserved amino acids
(considering ﬁve species) and were not identiﬁed in over
200 alleles of healthy individuals. One of the patients also
had two potentially disease-causing variants in the
MYBPC3 gene [2].
After the initial publication, CALR3 has been added to
the diagnostic arsenal of many molecular diagnostic
laboratories worldwide, including 15 laboratories listed in
the Genetic Testing Registry (https://www.ncbi.nlm.nih.
gov/gtr) as of 15 April 2018. However, since the initial
report, no other studies have conﬁrmed the association
between CALR3 and cardiomyopathy. The protein enco-
ded by the CALR3 gene, calreticulin-3, belongs to a
family of calcium-binding chaperones present in the
endoplasmic reticulum. Its exact function remains to be
determined. More recent studies have indicated that the
calcium-binding capacity of calreticulin-3 is absent or
very low [3], and that expression appears to be restricted
to the testis [4–7]. Here, we evaluate the genetic and
experimental evidence supporting a causal relationship.
For this purpose, we assessed the frequency, distribution
and potential effect of CALR3 variants in a Dutch cohort
of 6154 cardiomyopathy patients. In addition, we
investigated calreticulin-3 protein expression in heart
tissue from both patients and controls of different ages.
Finally, we discuss our ﬁndings in relation to existing
literature.
Materials and methods
Study population
The study population consisted of 6154 probands with a
clinical diagnosis of hypertrophic cardiomyopathy (HCM)
[8], dilated cardiomyopathy (DCM) [9], arrhythmogenic
right ventricular cardiomyopathy (ARVC) [10], or left
ventricular non-compaction (LVNC) [11], referred for
genetic testing of cardiomyopathy-related genes in ﬁve
molecular diagnostic laboratories in the Netherlands
between January 2012 and December 2016. Informed
consent was obtained from each patient prior to testing. In
probands with a rare heterozygous variant in CALR3, we
evaluated the outcome of cardiac screening and genetic
testing in relatives.
Variant analysis
Genomic DNA was extracted from peripheral blood sam-
ples according to standard protocols. Patients were tested
for at least 45 cardiomyopathy-related genes that are
included in the Dutch core panel: ABCC9, ACTC1, ACTN2,
ANKRD1, BAG3, CALR3, CRYAB, CSRP3, DES, DMD,
DSC2, DSG2, DSP, EMD, GLA, JPH2, JUP, LAMA4,
LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, MYL2,
MYL3, MYPN, MYOZ1, MYOZ2, PKP2, PLN, PRKAG2,
RBM20, RYR2, SCN5A, SGCD, TAZ, TCAP, TMEM43,
TNNC1, TNNI3, TNNT2, TPM1, TTN, and VCL. Genes
were analyzed in one of the participating laboratories either
by targeted enrichment via hybridization (n= 5104) or
selective circularization (n= 720) techniques, or whole-
exome sequencing-based testing of a virtual gene panel
(n= 330) [12–14]. In this study, we focused on sequence
variants in the CALR3 gene (NG_031959.2,
NM_145046.4). The pathogenicity of these variants was
assessed using Alamut Visual v2.7.2 software (Interactive
Biosoftware, Rouen, France), that integrates data from
large-scale population genetic studies, evolutionary con-
servation of nucleotides and amino acids, in silico missense
prediction tools (Align GVGD, SIFT, MutationTaster and
PolyPhen-2) and mRNA splicing prediction tools (Splice-
SiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer,
and Human Splicing Finder). Potential splice effect was
deﬁned as at least 10% difference between reference and
mutated scores by at least 3 out of 5 mRNA splicing pre-
diction tools. In addition, the deleteriousness of variants was
scored using combined annotation dependent depletion
(CADD) [15]. A scaled CADD score of 10, 20, or 30
indicates the top 10%, 1%, and 0.1% most deleterious
substitutions in the human genome, respectively. The
Mendelian clinically applicable pathogenicity (M-CAP)
score was added to improve classiﬁcation of rare
missense variants [16]. A threshold of 0.025 correctly dis-
misses 60% of variants of unknown signiﬁcance at 95%
sensitivity.
CALR3 variants with a minor allele frequency (MAF) >
0.1% in the Exome Aggregation Consortium (ExAC)
dataset (considering total population and major subpopula-
tions) [17], and synonymous and intronic variants without
predicted effect on mRNA splicing were excluded from
further analysis. Sanger sequencing was performed to
validate the remaining variants and to examine segregation
among family members. Additional variants in any of the
other cardiomyopathy-related genes were interpreted
according to the 2015 American College of Medical
Genetics and Genomics/Association of Molecular Pathol-
ogy (ACMG/AMP) guidelines [18], and classiﬁed into ﬁve
categories: “affects function”, “probably affects function”,
“effect unknown”, “probably does not affect function”, and
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“does not affect function”. The data resulting from this
study have been submitted to the corresponding Leiden
Open Variant Database at www.LOVD.nl/CALR3 (patient
IDs 163857–163904).
Haplotype analysis
To investigate whether the recurrent c.564del variant ori-
ginated from a single mutational event, we performed
haplotype analysis using eight highly polymorphic micro-
satellite markers spanning a 1.7 Mb region on chromosome
19p13.11 ﬂanking the CALR3 gene (D19S588, D19S244,
D19S711, D19S917, D19S199, D19S1899, D19S410, and
D19S915). Haplotypes were constructed from the genotype
data.
Statistical analysis
Sequence data for 60706 unrelated individuals assembled
by ExAC were used as an independent control dataset [19].
Raw data (release 0.3.1) were downloaded and ﬁltered
following the same strategy as for the patient cohort. Fre-
quencies were statistically compared using the χ2 test with
Yates’ correction. A p-value < 0.05 was considered statis-
tically signiﬁcant.
Immunohistochemistry
Immunohistochemical staining was performed on archived
myocardial samples from both patients with cardiomyo-
pathy and non-cardiac death. The ﬁrst group included one
individual with c.564del-positive DCM (49 years), and
three individuals with ischemic cardiomyopathy (37–62
years). The second group included 12 individuals who died
from non-cardiac causes, from four different age groups:
fetuses (19–23 weeks of gestation), neonates
(6 days–10 weeks), children (7–11 years), and adults
(30–57 years). Testicular biopsies were used as positive
controls. Samples were handled in accordance with the
Code of Conduct for dealing responsibly with human tissue
in the context of health research (FEDERA).
Tissue was ﬁxated using formalin 4% (v/v) and
embedded in parafﬁn. The sections (4 µm) were depar-
afﬁnized with xylene and rehydrated with ethanol, fol-
lowed by fully automated antigen retrieval and
immunostaining with ampliﬁcation steps on a Roche
Ventana Benchmark Ultra platform (Ventana Medical
Systems, Tucson, AZ, USA). Next, sections were incu-
bated during 1 h at room temperature with primary anti-
bodies, including a set of three different polyclonal rabbit
antibodies against CALR3: NBP1-33337, NBP2-33390,
and NBP2-33524 (Novus Biologicals, Littleton, CO,
USA). Negative controls were obtained by omitting the
primary antibody. Following visualization with the Opti-
View detection system (Ventana Medical Systems), slides
were examined using a light microscope (Leica Micro-
systems, Wetzlar, Germany).
Results
Genotypic and phenotypic characteristics
In our cohort of 6154 patients with cardiomyopathy, we
identiﬁed 46 unique heterozygous CALR3 variants. Of
these, 17 variants passed our selection criteria, including 12
missense, 1 synonymous, 1 nonsense, and 3 frameshift
variants (Table 1; Fig. 1). Eight variants clustered in the N-
terminal globular domain (Fig. 1), which is conserved
across the calreticulin family. Eight variants were found in
more than one family, resulting in a total of 48 probands
(Table 1). Phenotypes included asymmetric septal or con-
centric HCM, left ventricular or biventricular DCM, and
LVNC.
In nine probands (19%), the CALR3 variant was
accompanied by a putative disease-causing variant (“affects
function” or “probably affects function”) in another gene of
the cardiomyopathy panel (Supplemental Table 1), includ-
ing a heterozygous Dutch founder variant c.2373dup p.
(Trp792Valfs*41) in MYBPC3 (patient ID 163878, 163893
and 163894), a heterozygous missense variant c.481C>T p.
(Pro161Ser) in MYBPC3 (patient ID 163864), a hetero-
zygous splice variant c.442G>A p.(Gly148Arg) in
MYBCP3 (patient ID 163904), a heterozygous missense
variant c.4130C>T p.(Thr1377Met) in MYH7 (patient ID
163879), a homozygous nonsense variant c.376C>T p.
(Gln126*) in MYL2 (patient ID 163885), a heterozygous
nonsense variant in c.814C>T p.(Gln272*) in TNNT2
(patient ID 163861), and a truncating variant in
c.87722_87740del p.(Pro29241Leufs*24) in TTN (patient
ID 163900). In 17 other probands (35%), we found at least
one variant of unknown signiﬁcance (Supplemental
Table 1).
The most common variant, c.564del, was detected in 17
probands from all ﬁve laboratories, representing 0.28% of
the total cohort and 35% of all detected CALR3 variants.
Two of the probands (patient ID 163881 and 163888),
tested in different laboratories, were found to be close
relatives. A total of 44 relatives from nine probands had
been subsequently tested for the familial variant: 23 rela-
tives had a positive test result, and 21 relatives had a
negative test result. Four relatives were obligate hetero-
zygotes. Among the 27 (obligate) heterozygous relatives, 6
(22%) had cardiomyopathy, 17 (63%) had no overt cardiac
phenotype, and 4 were not examined (Table 2). Notably,
two affected relatives from a large four-generation family
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tested negative for the c.564del variant. One had severe
asymmetric septal hypertrophy (22 mm) in the absence of
hypertension. He did not have a variant in any of the other
cardiomyopathy genes upon further testing. The second
relative had left ventricular hypertrophy with a history or
hypertension, and may therefore be considered a
phenocopy.
In ﬁve probands with other CALR3 variants, additional
relatives were tested. The CALR3 variant did not segregate
with the phenotype in two of these families. In one family
(patient ID 163879), the CALR3 c.484A>G variant was
absent in a sibling whose son had died suddenly of HCM at
the age of 23 years. This sibling had, though, inherited the
accompanying disease-causing variant in the MYH7 gene.
Fig. 1 Schematic representation of the CALR3 gene and corresponding
protein domains: signal peptide (gray), N-domain (blue), P-domain
(orange) and C-domain (yellow). Boxes represent exons; connecting
lines represent intervening introns (unscaled). Rare heterozygous
CALR3 variants identiﬁed in this study are indicated in black. Variants
reported by Chiu et al. are indicated in red font. The regions recog-
nized by the primary antibodies used in this study are shown below the
graph
Table 1 Overview of rare heterozygous CALR3 variants identiﬁed in this study and their associated phenotypes
Nucleotide change Protein change # Probands Phenotype(s) ExAC
MAF
Splice
predictiona
CADD
score
M-CAP
score
c.21G>C p.(Gln7His) 4 HCM, DCM 5/61010 No effect 0.001 0.004
c.31A>G p.(Ile11Val) 1 HCM 1/62978 No effect 0.001 0.004
c.31A>C p.(Ile11Leu) 3 HCM, DCM Absent No effect 0.001 0.004
c.67T>A p.(Phe23Ile) 1 HCM 4/52406 No effect 31 0.125
c.72A>G p.(Gln24=) 1 HCM Absent Effect 1.581 N/A
c.147dup p.(Arg50*) 2 DCM, LVNC Absent No effect 24.6 N/A
c.403G>A p.(Asp135Asn) 7 HCM, DCM, LVNC,
mixed
11/108150 No effect 34 0.061
c.407T>C p.(Ile136Thr) 2 DCM Absent No effect 27.7 0.059
c.484A>G p.(Arg162Gly) 2 HCM Absent No effect 23.3 0.018
c.520C>A p.(Leu174Ile) 1 LVNC 4/121250 No effect 26.2 0.082
c.564del p.(Gln189Serfs*8) 17 HCM, DCM, LVNC,
mixed
5/121312 No effect 7.360 N/A
c.626C>T p.(Thr209Met) 1 HCM 1/121116 No effect 14.36 0.008
c.801del p.(Glu268Lysfs*13) 1 Mixed Absent No effect 4.736 N/A
c.833G>A p.(Arg278His) 2 HCM, DCM Absent No effect 22.3 0.017
c.860C>T p.(Thr287Met) 1 HCM 2/121410 No effect 9.523 0.021
c.1068_1069del p.(Glu357Glyfs*12) 1 DCM Absent No effect 35 N/A
c.1094C>G p.(Ser365Trp) 1 HCM Absent No effect 23.3 0.015
High pathogenicity scores (CADD ≥ 20 or M-CAP > 0.025) are displayed in bold
Reference sequences: NG_031959.2, NM_145046.4 (CALR3)
CADD Combined annotation dependent depletion, DCM dilated cardiomyopathy, ExAC Exome Aggregation Consortium, HCM hypertrophic
cardiomyopathy, LVNC left ventricular non-compaction, MAF minor allele frequency, M-CAP Mendelian clinically applicable pathogenicity, N/A
not applicable
aSplice effect was deﬁned as at least 10% difference between reference and mutated scores by at least 3 out of 5 mRNA splicing prediction tools
(SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer and Human Splicing Finder)
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In a second family (patient ID 163876), the c.407T>C
variant was absent in three affected relatives, including a
nephew with DCM and out-of-hospital cardiac arrest at the
age of 54 years.
In silico evaluation
Twelve of the CALR3 variants identiﬁed in our patient
cohort are predicted to result in an amino acid substitution
(Table 1). Six of these variants were absent from ExAC.
Four variants had high CADD (≥20) and M-CAP (>0.025)
scores, and are therefore more likely to have an effect on the
gene or protein function (Table 1).
The c.72A>G variant might affect mRNA splicing by the
introduction of a new acceptor splice site. However, the
effect could not be tested due to the lack of appropriate
mRNA-expressing tissues.
Four variants are predicted to result in a truncated pro-
tein. All but one variant (c.564del) were absent from ExAC
(Table 1). The c.564del variant predicts a frameshift starting
at position Gln189 and resulting in a premature termination
codon 7 amino acids downstream: p.(Gln189Serfs*8). This
variant was found at low frequency in the ExAC dataset,
and was conﬁned to the non-Finnish European population
(5/66,682 alleles, MAF= 0.0075%). The variant was absent
from the Genome of the Netherlands (GoNL, n= 250
parent–child trios) [20], the Rotterdam Study (ERGO,
n= 2628 elderly individuals from a suburb of the city of
Rotterdam) and the Erasmus Rucphen Family study (ERF,
n= 337 individuals from an isolated population in the
South-West of the Netherlands), and present once in our in-
house exome sequencing database of healthy parents (1/
1642 alleles, MAF= 0.061%).
Haplotype analysis
Haplotype analysis was performed in 12 of the families with
the most frequently observed variant c.564del (Supple-
mental Table 2). A shared haplotype for at least 4 of the 8
markers, located in a 1.2 Mb region surrounding the CALR3
gene, was observed in 6 families, suggesting that the variant
has arisen through a single mutational event in a common
ancestor. Therefore, it seems reasonable to exclude this
variant from the burden test (see below).
Burden test
The observed number of missense and truncating CALR3
variants in ExAC is approximately equal to the expected
number (Z-score −0.10 and pLI 0.00, respectively), indi-
cating that these variants seem to be tolerated [19]. Fol-
lowing the same ﬁltering steps used in our patient cohort,
the ExAC dataset contained 139 variants with potential
functional impact, including 118 missense, 2 synonymous,
8 nonsense, 2 start loss, 5 splice site, and 4 frameshift
variants. Approximately half of these variants (64/139=
46%) were located in the conserved N-domain, as was
observed in our patient cohort. The 139 variants were pre-
sent in 298/121,412 alleles, corresponding to 0.49% of the
control cohort. In comparison, we found 17 variants in 48/
12,308 alleles, corresponding to 0.78% of the patient cohort
(p= 0.0036). After excluding the c.564del variant, which
should probably be considered as a single mutational event
(see above), no statistically signiﬁcant difference was
observed (p= 0.89). Likewise, no difference was observed
when only missense variants were taken into account (p=
0.93).
Protein expression analysis
Previous studies, including the comprehensive collection
of data from the Genotype-Tissue Expression (GTEx)
project and the Human Protein Atlas (HPA), have
demonstrated testis-speciﬁc expression of CALR3 mRNA
and protein in adult human tissues [4–7]. To verify that
CALR3 is not expressed in the heart, in particular at
earlier time points, we performed immunohistochemical
staining in a series of myocardial tissues (from fetuses to
adults) using a set of three different antibodies against the
calreticulin-3 protein. Testicular samples were used as
positive controls. Calreticulin-3 expression was virtually
absent in myocardial tissues from each group (Fig. 2a–e).
We only observed some antibody-dependent staining of
vascular smooth muscle cells of arterioles (NBP2-33390),
stromal cells (NBP2-33390), and mast cells (NBP1-
33337). All three antibodies showed high expression of
the CALR3 protein in testicular germ cells (Fig. 2f), as
described previously [6, 7].
Table 2 Genotype–phenotype
relationships in relatives from
patients with the CALR3
c.564del variant
Phenotype positive Phenotype negative Phenotype unknown Total
Genotype positivea 6 17 4 27
Genotype negative 2 16 3 21
Total 8 33 7 48
aIncluding four obligate heterozygotes
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Discussion
We investigated the frequency and characteristics of
CALR3 variants in a large Dutch cardiomyopathy cohort.
Based on several observations in this study, we question
the impact of CALR3 genetic variation on cardiomyo-
pathy. (i) In approximately one-ﬁfth of the probands, the
CALR3 variant was accompanied by a disease-causing
variant in another, well-known cardiomyopathy gene.
Another 35% of probands had at least one variant of
unknown signiﬁcance in one of the other panel genes. (ii)
In 3 out of 14 families investigated in further detail, the
CALR3 variant did not segregate with the disease. (iii)
After exclusion of a Dutch founder variant, no statically
signiﬁcant difference was found in allele frequencies
between our patient cohort and the ExAC dataset (p=
0.89). (iv) We could not detect CALR3 protein expression
in myocardial tissue at various ages. This observation is in
line with previous studies, that reported testis-speciﬁc
expression [4–7].
Calreticulin-3 (also known as calsperin or calreticulin-2)
belongs to a family of calcium-binding chaperones localized
in the lumen of the endoplasmic reticulum. CALR3 is
mainly expressed in the reproductive system [6, 7, 21]. Its
exact role in both health and disease is still largely
unknown. Calreticulin-3 contains three functional domains:
a N-terminal globular domain, a proline-rich P-domain, and
a C-terminal acidic domain. The N-domain has a conserved
amino acid sequence with binding sites for zinc ions and
glycans. In contrast to other members of the calreticulin
family, the calcium-binding capacity of the P-domain and
the C-domain seems absent or low [3]. Its paralog calreti-
culin (CALR), on the other hand, encodes a ubiquitously
expressed protein that has been implicated in a variety of
cellular processes, including calcium homeostasis, protein
folding, and cell adhesion [22].
Fig. 2 Examples of
immunohistochemical staining
for CALR3 (antibody NBP2-
33390) in normal and affected
tissues. No expression in
myocardial tissue from
(a) patient with c.564del-
positive DCM, b patient with
ischemic cardiomyopathy, and
c child, d newborn, and e fetus
with structurally normal hearts.
Instead, we observed positive
staining of arteriolar smooth
muscle cells in all samples
(arrows). f High expression of
CALR3 in testicular germ cells
as positive control tissue. Scale
bars: 1 mm
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Chiu et al. were the ﬁrst to investigate the role of CALR3
in human, assuming that variants in this gene may lead to
calcium dysregulation with subsequent HCM. However, their
assumption is based on studies concerning the multi-
functional and ubiquitously expressed paralog CALR. Two
heterozygous missense variants in CALR3 (c.218G>A
p.(Arg73Gln) and c.245A>G p.(Lys82Arg)) were identiﬁed
in two unrelated patients with HCM [2]. The pathogenicity of
both variants can be questioned based on current data
resources. The c.218G>A variant affects a conserved
nucleotide and amino acid (considering 17 species). The
physicochemical difference between arginine and glutamine
is small (Grantham distance 34). PolyPhen-2 is the only
algorithm predicting a damaging effect. The variant is
observed at low frequency in ExAC (4/121412 alleles, MAF
= 0.0033%). The proband had two additional variants in
MYBPC3, c.2234A>G p.(Asp745Gly) and c.2618C>A
p.(Pro873His), which are present in the Human Gene
Mutation Database and more likely to account for the HCM.
The other CALR3 variant c.245A>G also affects a conserved
nucleotide and amino acid. The physicochemical difference
between lysine and arginine is small (Grantham distance 26).
The variant is observed at relatively high frequency in ExAC
(69/121412 alleles, MAF= 0.057%), and is therefore con-
sidered unlikely to be the cause of the disease [23, 24].
The CALR3 gene has been studied in several animal
models. Male Calr3 knockout mice were infertile due to
defective sperm migration and binding to the zona pellu-
cida; no other gross abnormalities were observed, speciﬁ-
cally no cardiac dysfunction [21]. Female Calr3 knockout
mice were completely normal. Zebraﬁsh have two orthologs
of CALR3: calr3a (NM_131047.2) and calr3b
(NM_201465.3). Knockdown of calr3a using antisense
morpholino oligonucleotides causes a reduction of posterior
lateral line neuromasts; superﬁcial sensory organs that
enable the ﬁsh to detect changes in water ﬂow. Cardiac
abnormalities were not reported [25]. No phenotypic data
are available on calr3b mutants. Calr knockout mice, on the
other hand, display impaired cardiac development and
function, resulting in early embryonic lethality [26].
Transgenic mice overexpressing calreticulin show pro-
gressive conduction abnormalities, leading to complete
heart block and early postnatal death [27]. These data
suggest that CALR, rather than CALR3, is a good candidate
gene for cardiac disease in humans.
Study limitations
Immunohistochemical staining showed absence of
calreticulin-3 expression in second-trimester fetal myo-
cardium. However, we cannot exclude the possibility that
calreticulin-3 is expressed at earlier stages of cardiac
development. In addition, although our data do not
support a role of CALR3 in cardiomyopathy as single-
gene disorder, a more complex pattern of inheritance
cannot be ruled out.
Conclusions
Based on our ﬁndings, we highly question the implication
of CALR3 in cardiomyopathy. Our data suggest that CALR3
variants are not monogenic causes of cardiomyopathy, if
cardiovascular disease-related at all.
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